A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis

Inclusion Criteria:

Provides signed and dated informed consent in accordance with local regulations.
18 to 65 years of age.
Diagnosis of MS.
Has had an inadequate response DMTs.
EDSS within protocol parameters.
Able and willing to undergo MRIs.
Must be clinically stable for 1 month prior to Day 1.

Exclusion Criteria:

Has a known or suspected hypersensitivity to human serum albumin, diphenhydramine, acetaminophen, methylprednisolone, or any of the components of IMS001.
Has history of excluded medications, per protocol, prior to Day 1.
Has a history of neoplastic disease except for basal cell carcinoma, non-metastatic squamous cell carcinoma of the skin that has been excised with clean margins, or adequately treated in-situ carcinoma of the cervix.
Prior history of any other autoimmune disease, myelodysplasia, or hematologic disease.
Prior treatment with any allogeneic cell therapy or tissue transplant.
Prior history of smoking equivalent to ˃20 cumulative pack years of cigarettes.
Recent clinically significant infection during the Screening Phase.
Has any medical or psychiatric condition that would impact outcome or participation in the study.
Has clinically significant abnormal findings on the electrocardiogram (ECG) during the Screening Phase.
Has known or documented human immunodeficiency virus (HIV) infection or active Hepatitis B, or C.
Has an elevated liver function test abnormality during the Screening Phase.
Has abnormalities of blood count during the Screening Phase.
Has laboratory abnormalities of renal function during the Screening Phase.
Has other clinically significant laboratory abnormalities during Screening Phase.
Body weight ≥120 kg.
Women pregnant, breast feeding, or planning to become pregnant during the study.
Is unavailable for the duration of the trial, is likely to be noncompliant with the protocol, or is generally felt to be unsuitable by the principal investigator.
Current or recent participation in any other clinical or device trials within 3 months prior to Day 1.